However, biologics targeting CD47 in clinical trials have exhibited clinical liabilities including 1) on-target toxicities leading to hemolytic anemia, neutropenia, and thrombocytopenia [50–54], 2) limited/variable tissue penetration and distribution into tumors, and 3) a large CD47 antigen sink in the vascular compartment [55]. The gene discussed is CD47; the disease is Decreased total neutrophil count.